PRDX5 and ovarian cancer: Elevated serum levels of TXN were observed in ovarian cancer compared to normal persons with non-cancer inflammatory disease [37], although, Criscuolo et al. showed reduced glutathione levels in HGSOC patients that did not respond to platinum-based therapy, resulting in the increased expression of thioredoxin reductase [38].